Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 3 de 3
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
J Pharm Pharmacol ; 75(2): 276-286, 2023 Feb 08.
Artículo en Inglés | MEDLINE | ID: mdl-36617180

RESUMEN

OBJECTIVES: To develop a sustained release 5-fluorouracil (5-FU) implant by three-dimensional (3D) printing to effectively prevent conjunctival fibrosis after glaucoma surgery. METHODS: 3D-printed implants composed of polycaprolactone (PCL) and chitosan (CS) were fabricated by heat extrusion technology and loaded with 1% 5-FU. Light microscopy and scanning electron microscopy were used to study the surface morphology. The 5-FU concentration released over 8 weeks was measured by ultraviolet visible spectroscopy. The effects on cell viability, fibroblast contractility and the expression of key fibrotic genes were assessed in human conjunctival fibroblasts. KEY FINDINGS: The PCL-CS-5-FU implant sustainably released 5-FU over 8 weeks and the peak concentration was over 6.1 µg/ml during weeks 1 and 2. The implant had a smooth surface and its total weight decreased by 3.5% after 8 weeks. The PCL-CS-5-FU implant did not affect cell viability in conjunctival fibroblasts and sustainably suppressed fibroblast contractility and key fibrotic genes for 8 weeks. CONCLUSIONS: The PCL-CS-5-FU implant was biocompatible and degradable with a significant effect in suppressing fibroblast contractility. The PCL-CS-5-FU implant could be used as a sustained release drug implant, replacing the need for repeated 5-FU injections in clinic, to prevent conjunctival fibrosis after glaucoma surgery.


Asunto(s)
Quitosano , Glaucoma , Humanos , Preparaciones de Acción Retardada/química , Fluorouracilo/farmacología , Quitosano/química , Impresión Tridimensional
2.
Int J Pharm ; 629: 122363, 2022 Dec 15.
Artículo en Inglés | MEDLINE | ID: mdl-36336202

RESUMEN

By carefully controlling the dose administered and the drug release rate from drug-eluting implants, safety and efficacy of the therapeutic agent dispensed can be improved. The present work focuses on the promising advantages of 3D Bioprinting process in developing two layers' implantable scaffolds. The two layers have different functions, in order to ensure a more effective and synergistic breast cancer therapy. First layer involves use of polymers such as Poly- ε-Caprolactone (PCL) and Chitosan (CS), and incorporation of 5-Fluorouracil (5-FU). The aim of the first layer is releasing the drug within 4 weeks, obtaining a prolonged and modified release. According to in vitro drug release tests performed, ∼32 % of 5-FU was released after one month, after an initial burst effect of 17.22 %. The sudden release of the drug into the body would quickly reach an effective therapeutic concentration, while the drug sustained release maintains an effective therapeutic concentration range during the administration time. The second layer is made exclusively from PCL as polymeric matrix, into which Gold Nanoparticles (AuNPs) were subsequently loaded, and its main purpose is to be radiation enhancement. The long biodegradation time of PCL would make the non-soluble scaffold an alternative to conventional chemotherapy, optimizing drug release to the specific needs of the patients.


Asunto(s)
Neoplasias de la Mama , Nanopartículas del Metal , Humanos , Femenino , Poliésteres/uso terapéutico , Neoplasias de la Mama/tratamiento farmacológico , Oro/uso terapéutico , Fluorouracilo , Polímeros/uso terapéutico , Implantes de Medicamentos , Impresión Tridimensional
3.
Sci Robot ; 5(38)2020 01 29.
Artículo en Inglés | MEDLINE | ID: mdl-33022594

RESUMEN

Small-scale drones have enough sensing and computing power to find use across a growing number of applications. However, flying in the low-Reynolds number regime remains challenging. High sensitivity to atmospheric turbulence compromises vehicle stability and control, and low aerodynamic efficiency limits flight duration. Conventional wing designs have thus far failed to address these two deficiencies simultaneously. Here, we draw inspiration from nature's small flyers to design a wing with lift generation robust to gusts and freestream turbulence without sacrificing aerodynamic efficiency. This performance is achieved by forcing flow separation at the airfoil leading edge. Water and wind tunnel measurements are used to demonstrate the working principle and aerodynamic performance of the wing, showing a substantial reduction in the sensitivity of lift force production to freestream turbulence, as compared with the performance of an Eppler E423 low-Reynolds number wing. The minimum cruise power of a custom-built 104-gram fixed-wing drone equipped with the Separated Flow wing was measured in the wind tunnel indicating an upper limit for the flight time of 170 minutes, which is about four times higher than comparable existing fixed-wing drones. In addition, we present scaling guidelines and outline future design and manufacturing challenges.

SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA